<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ACR 2025 Vasculitis Resources | Alison Bays, MD</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #f5f0f0 0%, #fff5f5 100%);
            min-height: 100vh;
            color: #19375f;
        }

        .header {
            background: linear-gradient(135deg, #19375f 0%, #2d5a8c 100%);
            color: white;
            padding: 2rem;
            text-align: center;
        }

        .header h1 {
            font-size: 2.5rem;
            margin-bottom: 0.5rem;
        }

        .header p {
            opacity: 0.9;
            font-size: 1.1rem;
        }

        .author-info {
            margin-bottom: 1rem;
        }

        .author-info a {
            color: #ffd700;
            text-decoration: none;
            margin: 0 0.5rem;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 2rem;
        }

        .section {
            background: white;
            border-radius: 12px;
            padding: 1.5rem;
            margin-bottom: 1.5rem;
            box-shadow: 0 2px 8px rgba(25, 55, 95, 0.1);
            border-left: 4px solid #19375f;
        }

        .section h2 {
            color: #19375f;
            margin-bottom: 1rem;
            font-size: 1.5rem;
        }

        .section h3 {
            color: #19375f;
            margin: 1rem 0 0.5rem 0;
            font-size: 1.1rem;
        }

        .trial-card {
            background: linear-gradient(135deg, #fff5f5 0%, #ffe4e9 100%);
            border-radius: 8px;
            padding: 1rem;
            margin-bottom: 0.75rem;
        }

        .trial-card h4 {
            color: #19375f;
            margin-bottom: 0.25rem;
            display: flex;
            align-items: center;
            gap: 0.5rem;
            flex-wrap: wrap;
        }

        .tag {
            font-size: 0.7rem;
            padding: 0.2rem 0.5rem;
            border-radius: 4px;
            font-weight: bold;
        }

        .tag-gca { background: #e3f2fd; color: #1565c0; }
        .tag-egpa { background: #fff3e0; color: #e65100; }
        .tag-aav { background: #e8f5e9; color: #2e7d32; }
        .tag-igg4 { background: #f3e5f5; color: #7b1fa2; }
        .tag-other { background: #fce4ec; color: #c2185b; }

        .trial-links {
            margin-top: 0.5rem;
            font-size: 0.9rem;
        }

        .trial-links a {
            color: #2d5a8c;
            text-decoration: none;
            margin-right: 1rem;
        }

        .trial-links a:hover {
            text-decoration: underline;
        }

        .abstract-item {
            background: #fffbf0;
            border-left: 3px solid #ffc107;
            padding: 0.5rem 0.75rem;
            margin-bottom: 0.5rem;
            border-radius: 0 4px 4px 0;
        }

        .abstract-item a {
            color: #19375f;
            text-decoration: none;
        }

        .abstract-item a:hover {
            text-decoration: underline;
        }

        .abstract-number {
            font-weight: bold;
            color: #19375f;
        }

        .guidelines-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 1rem;
            margin-top: 1rem;
        }

        .guideline-card {
            background: #f8f9fa;
            padding: 1rem;
            border-radius: 8px;
            text-align: center;
        }

        .guideline-card h4 {
            color: #19375f;
            margin-bottom: 0.5rem;
        }

        .guideline-card p {
            font-size: 0.9rem;
            color: #666;
            margin-bottom: 0.5rem;
        }

        .guideline-card a {
            color: #2d5a8c;
            text-decoration: none;
        }

        .footer {
            background: #19375f;
            color: white;
            text-align: center;
            padding: 2rem;
            margin-top: 2rem;
        }

        .footer a {
            color: white;
            text-decoration: none;
            display: inline-block;
            margin: 0.5rem 1rem;
            padding: 0.5rem 1rem;
            border: 1px solid rgba(255,255,255,0.3);
            border-radius: 20px;
        }

        .footer a:hover {
            background: rgba(255,255,255,0.1);
        }

        .late-breaking {
            background: linear-gradient(135deg, #fff8e1 0%, #ffecb3 100%);
            border-left-color: #ffc107;
        }

        @media (max-width: 768px) {
            .header h1 { font-size: 1.8rem; }
            .container { padding: 1rem; }
        }
    </style>
</head>
<body>
    <div class="header">
        <div class="author-info">
            <strong>Alison Bays, MD</strong><br>
            <a href="https://rheumify.org">üåê Rheumify.org</a> ‚Ä¢
            <a href="https://rheumify.substack.com">üì∞ Substack</a>
        </div>
        <h1>ü©∫ ACR Convergence 2025</h1>
        <p>Vasculitis Highlights & Resources</p>
        <p>Chicago, IL ‚Ä¢ November 14-19, 2025</p>
    </div>

    <div class="container">
        <!-- Key Trials Section -->
        <div class="section">
            <h2>üîë Key Trials & Publications</h2>

            <div class="trial-card">
                <h4>SELECT-GCA (NEJM 2025) <span class="tag tag-gca">GCA</span></h4>
                <div class="trial-links">
                    ‚Üí <a href="https://acrabstracts.org/abstract/efficacy-and-safety-of-upadacitinib-in-giant-cell-arteritis-results-from-a-phase-3-randomized-controlled-trial/">ACR Abstract</a> |
                    ‚Üí <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2413449">NEJM Publication</a>
                </div>
            </div>

            <div class="trial-card">
                <h4>METOGiA Trial (ACR 2025) <span class="tag tag-gca">GCA</span></h4>
                <div class="trial-links">
                    ‚Üí <a href="https://acrabstracts.org/abstract/methotrexate-versus-tocilizumab-in-patients-with-newly-diagnosed-giant-cell-arteritis-the-metogia-trial/">ACR Abstract</a>
                </div>
            </div>

            <div class="trial-card">
                <h4>MANDARA (NEJM 2024) <span class="tag tag-egpa">EGPA</span></h4>
                <div class="trial-links">
                    ‚Üí <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2405091">NEJM Publication</a>
                </div>
            </div>

            <div class="trial-card">
                <h4>MITIGATE Trial (NEJM 2024) <span class="tag tag-igg4">IgG4-RD</span></h4>
                <div class="trial-links">
                    ‚Üí <a href="https://acrabstracts.org/abstract/inebilizumab-in-igg4-related-disease-primary-efficacy-and-safety-results-from-the-phase-3-mitigate-trial/">ACR Abstract</a> |
                    ‚Üí <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2409712">NEJM Publication</a>
                </div>
            </div>
        </div>

        <!-- GCA Abstracts -->
        <div class="section">
            <h2>üî¨ Giant Cell Arteritis Abstracts</h2>

            <h3>SELECT-GCA & Upadacitinib</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/efficacy-and-safety-of-upadacitinib-in-giant-cell-arteritis-results-from-a-phase-3-randomized-controlled-trial/"><span class="abstract-number">#0776</span> SELECT-GCA: Phase 3 Trial Results</a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/efficacy-and-safety-of-upadacitinib-in-giant-cell-arteritis-2-year-results-from-a-phase-3-randomized-controlled-trial/"><span class="abstract-number">#0895</span> SELECT-GCA: 2-Year Extension Results</a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/mosaic-loss-of-y-chromosome-and-relapse-of-giant-cell-arteritis/"><span class="abstract-number">#0892</span> Y Chromosome Loss & GCA Relapse</a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/real-world-effectiveness-of-janus-kinase-inhibitors-in-giant-cell-arteritis/"><span class="abstract-number">#0737</span> Real-World JAK Inhibitor Effectiveness in GCA</a>
            </div>

            <h3>METOGiA & Tocilizumab Studies</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/methotrexate-versus-tocilizumab-in-patients-with-newly-diagnosed-giant-cell-arteritis-the-metogia-trial/"><span class="abstract-number">#0891</span> METOGiA: MTX vs TCZ for GCA</a>
            </div>
        </div>

        <!-- EGPA Abstracts -->
        <div class="section">
            <h2>üî¨ EGPA Abstracts</h2>

            <h3>MANDARA Trial & Anti-IL5 Therapy</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/efficacy-of-anti-il-5-r-therapies-on-specific-disease-manifestations-of-eosinophilic-granulomatosis-with-polyangiitis/"><span class="abstract-number">ACR 2025</span> MANDARA 2-Year: Efficacy on Disease Manifestations</a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/classification-of-relapses-of-eosinophilic-granulomatosis-with-polyangiitis-after-two-years-of-treatment-with-anti-interleukin-5-receptor-therapy/"><span class="abstract-number">ACR 2025</span> MANDARA 2-Year: Classification of Relapses</a>
            </div>
            <div class="abstract-item">
                <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2405091"><span class="abstract-number">NEJM 2024</span> MANDARA Primary Results</a>
            </div>
        </div>

        <!-- AAV Abstracts -->
        <div class="section">
            <h2>üî¨ ANCA-Associated Vasculitis Abstracts</h2>

            <h3>Avacopan & Safety</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/real-world-drug-induced-liver-injury-associated-with-avacopan-use-in-anca-associated-vasculitis/"><span class="abstract-number">#0724</span> Avacopan Liver Injury Risk: Real-World Data</a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/avacopan-safety-combined-data-from-three-clinical-trials/"><span class="abstract-number">#1825</span> Avacopan Safety: Combined Trial Data</a>
            </div>

            <h3>Outcomes & Prognostic Tools</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/the-danger-score-a-mortality-predictor-in-anca-associated-vasculitis/"><span class="abstract-number">#2521</span> DANGER Score: Mortality Predictor in AAV</a>
            </div>

            <h3>Trial Diversity & Equity</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/diversity-in-anca-associated-vasculitis-and-giant-cell-arteritis-clinical-trials/"><span class="abstract-number">#1842</span> Diversity in AAV & GCA Clinical Trials</a>
            </div>
        </div>

        <!-- IgG4-RD Abstracts -->
        <div class="section">
            <h2>üî¨ IgG4-Related Disease Abstracts</h2>

            <h3>MITIGATE Trial & Inebilizumab</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/inebilizumab-in-igg4-related-disease-primary-efficacy-and-safety-results-from-the-phase-3-mitigate-trial/"><span class="abstract-number">#0944</span> MITIGATE Phase 3: Primary Efficacy & Safety</a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/inebilizumab-in-igg4-related-disease-biomarker-analysis/"><span class="abstract-number">ACR 2025</span> MITIGATE Biomarker Analysis</a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/inebilizumab-in-igg4-related-disease-subgroup-analysis/"><span class="abstract-number">ACR 2025</span> MITIGATE Subgroup Analysis</a>
            </div>

            <h3>Treatment & Management</h3>
            <div class="abstract-item late-breaking">
                <a href="https://acrabstracts.org/abstract/tofacitinib-plus-glucocorticoids-versus-glucocorticoids-alone-for-igg4-related-disease/"><span class="abstract-number">LB02</span> ‚≠ê LATE-BREAKING: Tofacitinib + GC Reduces Relapse (RCT)</a>
            </div>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/rilzabrutinib-in-igg4-related-disease/"><span class="abstract-number">ACR 2025</span> Rilzabrutinib (BTK Inhibitor) Phase 2 Results</a>
            </div>
        </div>

        <!-- Other Vasculitis -->
        <div class="section">
            <h2>üî¨ Other Vasculitis Abstracts</h2>

            <h3>IgA Vasculitis & Small Vessel</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/cutaneous-iga-vasculitis-target-trial/"><span class="abstract-number">ACR 2025</span> Cutaneous IgA Vasculitis: Colchicine vs Dapsone vs GC</a>
            </div>

            <h3>Takayasu Arteritis</h3>
            <div class="abstract-item">
                <a href="https://acrabstracts.org/abstract/taidai-takayasu-arteritis-integrated-disease-activity-index/"><span class="abstract-number">ACR 2025</span> TAIDAI: New Takayasu's Arteritis Disease Activity Index</a>
            </div>

            <h3>Large Vessel Vasculitis Guidelines</h3>
            <div class="abstract-item">
                <a href="https://ard.bmj.com/content/early/2024/01/15/ard-2024-225364"><span class="abstract-number">2025</span> EULAR PMR & LVV Recommendations</a>
            </div>
        </div>

        <!-- Guidelines -->
        <div class="section">
            <h2>üìã Guidelines & Resources</h2>
            <div class="guidelines-grid">
                <div class="guideline-card">
                    <h4>BSR 2025 AAV Guidelines</h4>
                    <p>Updated management recommendations</p>
                    <a href="https://academic.oup.com/rheumatology/article/63/1/17/7259123">View Guidelines ‚Üí</a>
                </div>
                <div class="guideline-card">
                    <h4>ACR/VF GCA & TAK Guidelines</h4>
                    <p>2021 Management Guidelines</p>
                    <a href="https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Giant-Cell-Arteritis">View Guidelines ‚Üí</a>
                </div>
                <div class="guideline-card">
                    <h4>Vasculitis Foundation</h4>
                    <p>Patient & Provider Resources</p>
                    <a href="https://www.vasculitisfoundation.org/">Visit Site ‚Üí</a>
                </div>
                <div class="guideline-card">
                    <h4>ACR Abstract Database</h4>
                    <p>Search all ACR 2025 abstracts</p>
                    <a href="https://acrabstracts.org/">Search Abstracts ‚Üí</a>
                </div>
            </div>
        </div>
    </div>

    <div class="footer">
        <p>Compiled by <strong>Alison Bays, MD</strong></p>
        <p>ACR Convergence 2025 ‚Ä¢ Chicago, IL</p>
        <div>
            <a href="https://rheumify.org">üåê Rheumify.org</a>
            <a href="https://rheumify.substack.com">üì∞ Rheumify Substack</a>
        </div>
        <p style="margin-top: 1rem; font-size: 0.9rem; opacity: 0.8;">For educational purposes only. Always verify with primary sources.</p>
    </div>
</body>
</html>
